Literature DB >> 25267585

Frequency of TERT promoter mutations in primary tumors of the liver.

Alexander Quaas1, Theresa Oldopp, Lars Tharun, Catina Klingenfeld, Till Krech, Guido Sauter, Tobias J Grob.   

Abstract

Transcriptional regulation of the TERT gene is a major cause of the cancer-specific increase in telomerase activity. Recently, frequent somatic mutations in the TERT promoter have been described in several tumor entities such as melanoma, glioblastoma, bladder cancer, and hepatocellular carcinoma. By generating a putative consensus binding site for ETS transcription factors within the TERT promoter, these mutations are predicted to increase promoter activity and TERT transcription. In order to improve the understanding of the role of TERT promoter mutation in liver tumorigenesis, the mutational status of the TERT promoter was analyzed in 78 hepatocellular carcinomas, 15 hepatocellular adenomas, and 52 intrahepatic cholangiocarciomas. The promoter region of TERT was screened for the two hotspot mutations using PCR and restriction fragment length analysis, utilizing the introduction of novel restriction sites by the somatic mutations. TERT promoter mutation was found in 37 of 78 hepatocellular carcinomas (47 %) and was restricted to the -124C>T mutation. Frequency of mutations was associated with grade of differentiation ranging from 39 % in well-differentiated tumors to 73 % in high-grade hepatocellular carcinomas. TERT promoter mutations were not found in 15 hepatocellular adenomas and 52 intrahepatic cholangiocarcinomas. These data show that TERT promoter mutation is the most frequent genetic alteration in hepatocellular carcinoma known at this time. The striking predominance of the -124C>T mutation compared with other tumor entities suggest a biological difference of the two hotspot mutations. Analysis of TERT promoter mutation might become a diagnostic tool distinguishing hepatocellular adenoma from well-differentiated hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25267585     DOI: 10.1007/s00428-014-1658-7

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  18 in total

1.  Frequency of TERT promoter mutations in human cancers.

Authors:  João Vinagre; Ana Almeida; Helena Pópulo; Rui Batista; Joana Lyra; Vasco Pinto; Ricardo Coelho; Ricardo Celestino; Hugo Prazeres; Luis Lima; Miguel Melo; Adriana Gaspar da Rocha; Ana Preto; Patrícia Castro; Ligia Castro; Fernando Pardal; José Manuel Lopes; Lúcio Lara Santos; Rui Manuel Reis; José Cameselle-Teijeiro; Manuel Sobrinho-Simões; Jorge Lima; Valdemar Máximo; Paula Soares
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

Review 2.  Cholangiocarcinoma.

Authors:  Tushar Patel
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2006-01

3.  Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine.

Authors:  Carolyn D Hurst; Fiona M Platt; Margaret A Knowles
Journal:  Eur Urol       Date:  2013-09-03       Impact factor: 20.096

Review 4.  Fibrolamellar hepatocellular carcinoma.

Authors:  Shu Liu; Kwok Wah Chan; Bingyuan Wang; Liang Qiao
Journal:  Am J Gastroenterol       Date:  2009-07-28       Impact factor: 10.864

5.  TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine.

Authors:  Isaac Kinde; Enrico Munari; Sheila F Faraj; Ralph H Hruban; Mark Schoenberg; Trinity Bivalacqua; Mohamad Allaf; Simeon Springer; Yuxuan Wang; Luis A Diaz; Kenneth W Kinzler; Bert Vogelstein; Nickolas Papadopoulos; George J Netto
Journal:  Cancer Res       Date:  2013-10-11       Impact factor: 12.701

6.  Comparison of tumor pathology with duration of survival of North American patients with hepatocellular carcinoma.

Authors:  U C Nzeako; Z D Goodman; K G Ishak
Journal:  Cancer       Date:  1995-08-15       Impact factor: 6.860

Review 7.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

8.  Cofactor requirement of HpyAV restriction endonuclease.

Authors:  Siu-Hong Chan; Lars Opitz; Lauren Higgins; Diana O'loane; Shuang-Yong Xu
Journal:  PLoS One       Date:  2010-02-05       Impact factor: 3.240

Review 9.  Hepatocellular benign tumors-from molecular classification to personalized clinical care.

Authors:  Jean-Charles Nault; Paulette Bioulac-Sage; Jessica Zucman-Rossi
Journal:  Gastroenterology       Date:  2013-02-26       Impact factor: 22.682

10.  TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism.

Authors:  P Sivaramakrishna Rachakonda; Ismail Hosen; Petra J de Verdier; Mahdi Fallah; Barbara Heidenreich; Charlotta Ryk; N Peter Wiklund; Gunnar Steineck; Dirk Schadendorf; Kari Hemminki; Rajiv Kumar
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-07       Impact factor: 11.205

View more
  27 in total

Review 1.  Stop pulling my strings - what telomeres taught us about the DNA damage response.

Authors:  Eros Lazzerini-Denchi; Agnel Sfeir
Journal:  Nat Rev Mol Cell Biol       Date:  2016-05-11       Impact factor: 94.444

2.  Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer.

Authors:  Robert J A Bell; H Tomas Rube; Alex Kreig; Andrew Mancini; Shaun D Fouse; Raman P Nagarajan; Serah Choi; Chibo Hong; Daniel He; Melike Pekmezci; John K Wiencke; Margaret R Wrensch; Susan M Chang; Kyle M Walsh; Sua Myong; Jun S Song; Joseph F Costello
Journal:  Science       Date:  2015-05-14       Impact factor: 47.728

Review 3.  Telomeres in cancer: tumour suppression and genome instability.

Authors:  John Maciejowski; Titia de Lange
Journal:  Nat Rev Mol Cell Biol       Date:  2017-01-18       Impact factor: 94.444

4.  Aberrant expression of ETS1 and ETS2 proteins in cancer.

Authors:  Elizabeth A Fry; Kazushi Inoue
Journal:  Cancer Rep Rev       Date:  2018-04-23

Review 5.  Correlation of molecular alterations with pathological features in hepatocellular carcinoma: Literature review and experience of an Italian center.

Authors:  Thais Maloberti; Antonio De Leo; Viviana Sanza; Elisa Gruppioni; Annalisa Altimari; Mattia Riefolo; Michela Visani; Deborah Malvi; Antonia D'Errico; Giovanni Tallini; Francesco Vasuri; Dario de Biase
Journal:  World J Gastroenterol       Date:  2022-07-07       Impact factor: 5.374

6.  De novo identification of maximally deregulated subnetworks based on multi-omics data with DeRegNet.

Authors:  Sebastian Winkler; Ivana Winkler; Mirjam Figaschewski; Thorsten Tiede; Alfred Nordheim; Oliver Kohlbacher
Journal:  BMC Bioinformatics       Date:  2022-04-19       Impact factor: 3.307

Review 7.  Understanding TERT Promoter Mutations: A Common Path to Immortality.

Authors:  Robert J A Bell; H Tomas Rube; Ana Xavier-Magalhães; Bruno M Costa; Andrew Mancini; Jun S Song; Joseph F Costello
Journal:  Mol Cancer Res       Date:  2016-03-03       Impact factor: 5.852

Review 8.  Latest developments in precancerous lesions of hepatocellular carcinoma.

Authors:  Zhao-Shan Niu; Xiao-Jun Niu; Wen-Hong Wang; Jing Zhao
Journal:  World J Gastroenterol       Date:  2016-03-28       Impact factor: 5.742

Review 9.  The role of telomeres and telomerase in cirrhosis and liver cancer.

Authors:  Jean-Charles Nault; Massih Ningarhari; Sandra Rebouissou; Jessica Zucman-Rossi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-06-28       Impact factor: 46.802

10.  Recurrent HBV Integration Targets as Potential Drivers in Hepatocellular Carcinoma.

Authors:  Selena Y Lin; Adam Zhang; Jessica Lian; Jeremy Wang; Ting-Tsung Chang; Yih-Jyh Lin; Wei Song; Ying-Hsiu Su
Journal:  Cells       Date:  2021-05-23       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.